BRPF1: A Potential Drug Target and Biomarker for Cardiovascular Diseases

Target Name: BRPF1

NCBI ID: G7862

BRPF1: A Potential Drug Target and Biomarker for Cardiovascular Diseases

BRPF1 (Peripheral Responsiveness-Predictable Fractional Flow), also known as Peregrin, is a protein that is expressed in the endothelium, which is the lining of the blood vessels. It is a potential drug target and biomarker for various cardiovascular diseases, including hypertension, heart failure, and cancer.

BRPF1 is a transmembrane protein that is characterized by its unique structure. It consists of a long extracellular domain that is involved in cell signaling and a short intracellular domain that is involved in protein-protein interactions. The extracellular domain of BRPF1 is composed of a unique repeat sequence that is conserved in various species, including humans.

BRPF1 functions as a negative regulator of the Shc/Tal1 signaling pathway, which is a critical pathway for cell signaling and survival. The Shc/Tal1 signaling pathway is involved in the regulation of cell growth, apoptosis, and angiogenesis, and is a target of many diseases, including cancer.

BRPF1 functions as a negative regulator of the Shc/Tal1 signaling pathway by inhibiting the activity of the transcription factor, Tal, which is a key player in this pathway. Tal is involved in the regulation of cell growth, apoptosis, and angiogenesis, and is a target of many diseases, including cancer.

BRPF1 is also involved in the regulation of the Notch signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival. The Notch signaling pathway is a critical pathway for the development and maintenance of tissues and organs, and is involved in many diseases, including cancer.

BRPF1 is a potential drug target because of its involvement in the regulation of the Shc/Tal1 and Notch signaling pathways, which are involved in the regulation of many diseases. Additionally, its unique structure and conservation in various species make it an attractive target for drug development.

BRPF1 is also a potential biomarker for various cardiovascular diseases, including hypertension, heart failure, and cancer. Its expression is often decreased in these diseases, and its levels can be used as a diagnostic marker or a target for drug development.

BRPF1 is expressed in various tissues and cells, including endothelial cells, smooth muscle cells, and cardiac muscle cells. It is involved in the regulation of cell signaling and protein-protein interactions, and its dysfunction is implicated in the development and progression of many cardiovascular diseases.

BRPF1 is a small molecule that can be targeted by small molecule inhibitors, making it an attractive target for drug development. Studies have shown that inhibitors of BRPF1 have the potential to treat various cardiovascular diseases, including hypertension, heart failure, and cancer.

In conclusion, BRPF1 is a protein that is expressed in the endothelium and is involved in the regulation of the Shc/Tal1 and Notch signaling pathways. Its unique structure and conservation in various species make it an attractive target for drug development. Its potential as a drug target and biomarker for cardiovascular diseases makes it a promising target for future research.

Protein Name: Bromodomain And PHD Finger Containing 1

Functions: Scaffold subunit of various histone acetyltransferase (HAT) complexes, such as the MOZ/MORF and HBO1 complexes, which have a histone H3 acetyltransferase activity (PubMed:16387653, PubMed:24065767, PubMed:27939640). Plays a key role in HBO1 complex by directing KAT7/HBO1 specificity towards histone H3 'Lys-14' acetylation (H3K14ac) (PubMed:24065767). Some HAT complexes preferentially mediate histone H3 'Lys-23' (H3K23ac) acetylation (PubMed:27939640). Positively regulates the transcription of RUNX1 and RUNX2 (PubMed:18794358)

More Common Targets